Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism

被引:48
|
作者
Bogenschutz, Michael P. [1 ]
Forcehimes, Alyssa A. [2 ]
机构
[1] NYU, Sch Med, Dept Psychiat, New York, NY USA
[2] Train Change Inc, Phoenix, AZ USA
关键词
alcoholism; alcohol use disorder; psilocybin; hallucinogen; psychedelic; psychotherapy; LYSERGIC-ACID DIETHYLAMIDE; RANDOMIZED CONTROLLED-TRIALS; MESSENGER-RNA EXPRESSION; RELAPSE PREVENTION; LSD TREATMENT; FUNCTIONAL CONNECTIVITY; PSYCHEDELIC EXPERIENCE; SEROTONIN RECEPTOR; USE DISORDERS; PEYOTE USE;
D O I
10.1177/0022167816673493
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Research activity on the potential clinical value of classic hallucinogens and other psychedelics has increased markedly in the past two decades, and promises to continue to expand. Experimental study of hallucinogen-assisted treatment, and any future clinical use, requires the development of psychotherapeutic models that are appropriate to the disorder being treated and effectively integrated with the pharmacologic component of the treatment. To provide a framework for thinking about possible treatment models, we provide an overview of the history of psychedelic-assisted treatment, review what is known about the therapeutic mechanisms of these treatments, and consider the various purposes of psychotherapy in the context of both research and clinical use of psychedelic-assisted treatment. We then provide a description of a therapy model we have developed and are currently using in a trial of psilocybin-assisted treatment for alcoholism. Finally, we discuss advantages and disadvantages of a range of alternative models, emphasizing the need for research to determine the most effective treatment models for any indications for which efficacy becomes established.
引用
收藏
页码:389 / 414
页数:26
相关论文
共 50 条
  • [21] Psilocybin-Assisted Treatment of Major Depressive Disorder: Results From a Randomized Trial
    Griffiths, Roland
    Barrett, Frederick
    Darrick, May
    Johnson, Matthew
    Mary, Cosimano
    Patrick, Finan
    Alan, Davis
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 439 - 439
  • [22] Integrating Psilocybin-Assisted Psychotherapy Into Comprehensive Cancer Care
    Bogenschutz, MiChaEl P.
    ONCOLOGY-NEW YORK, 2025, 39 (02):
  • [23] Psilocybin-assisted therapy and HIV-related shame
    Mehtani, Nicky J.
    Johnson, Mallory O.
    Hendricks, Peter S.
    Mitchell, Jennifer
    Anderson, Brian T.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [24] Psilocybin-assisted group therapy: A new hope for demoralization
    Hendricks, Peter S.
    ECLINICALMEDICINE, 2020, 27
  • [25] Psilocybin-assisted psychotherapy as a potential treatment for eating disorders: a narrative review of preliminary evidence
    Koning, Elena
    Brietzke, Elisa
    TRENDS IN PSYCHIATRY AND PSYCHOTHERAPY, 2024, 46
  • [26] Improving Access to Psilocybin-Assisted Therapy: Barriers, Challenges, and Recommendations
    Tsang, V.
    Roney, C.
    EUROPEAN PSYCHIATRY, 2024, 67 : S601 - S601
  • [27] SPONTANEOUS CHANGES IN CIGARETTE SMOKING FOLLOWING PSILOCYBIN-ASSISTED TREATMENT FOR ALCOHOL USE DISORDER
    Pagni, Broc
    Gold, Noah
    Bogenschutz, Michael
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260
  • [28] How Important Is a Guide Who Has Taken Psilocybin in Psilocybin-Assisted Therapy for Depression?
    Earleywine, Mitch
    Low, Fiona
    Altman, Brianna R.
    De Leo, Joseph
    JOURNAL OF PSYCHOACTIVE DRUGS, 2023, 55 (01) : 51 - 61
  • [29] Psilocybin-assisted psychotherapy for cancer-related anxiety and depression
    Yaniv, Dan
    Ramondetta, Lois Michelle
    Cohen, Lorenzo
    Amit, Moran
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (08) : 1327 - 1328
  • [30] Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report
    Do, Andre
    Michaud, Vanessa
    Stephan, Jean-Francois
    Moreau, Miltiadis
    Benoit, Elise
    Berube, Felix-Antoine
    Bibaud-De Serres, Antoine
    Taillefer, Alain
    Vincent, Philippe
    FRONTIERS IN PSYCHIATRY, 2024, 15